Novo Nordisk Partners With OpenAI To Accelerate AI-Driven Drug Development, Transform Healthcare with AI Innovation

Novo Nordisk has announced a strategic partnership with OpenAI to accelerate the use of artificial intelligence across its operations and drug development pipeline. The collaboration is designed to help the company bring innovative treatments to patients faster by leveraging advanced AI capabilities.

Under the agreement, AI will be applied to analyse complex datasets, identify promising drug candidates, and streamline the journey from early research to clinical application. The partnership also emphasises strong data governance, ethical use, and human oversight to ensure compliance with regulatory standards while maximizing the benefits of AI-driven insights.

“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” said Sam Altman, CEO of OpenAI. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”

Beyond research and development, the collaboration will extend to improving efficiency across manufacturing, supply chain, distribution, and corporate functions. OpenAI will also support Novo Nordisk in enhancing AI literacy and upskilling its global workforce, enabling broader adoption of advanced technologies across the organization.

“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Mike Doustdar, president and CEO of Novo Nordisk. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.” 

Pilot programs are set to begin across key business areas, including R&D, manufacturing, and commercial operations, with full-scale integration expected by the end of 2026. This partnership builds on Novo Nordisk’s ongoing investments in AI and its collaborations with technology and research partners to strengthen its digital capabilities.